Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 875 versus BICILLIN L A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 875 versus BICILLIN L A.
AUGMENTIN '875' vs BICILLIN L-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.
Penicillin G benzathine is a slow-release formulation that provides prolonged tissue concentrations. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes, leading to cell lysis.
One 875 mg amoxicillin/125 mg clavulanate tablet orally every 12 hours.
1.2 million units intramuscularly as a single dose for treatment of streptococcal pharyngitis; for syphilis, 2.4 million units intramuscularly weekly for 1-3 weeks depending on stage.
None Documented
None Documented
Amoxicillin: 1-1.5 hours (may extend to 7-13 hours in renal impairment). Clavulanate: ~1 hour (may extend to 2.5-4.5 hours in renal impairment).
Terminal half-life: 30-60 hours (prolonged due to slow absorption from IM depot; clinically allows single-dose regimen for syphilis)
Amoxicillin: ~50-70% renal as unchanged drug, 10-20% biliary. Clavulanate: ~30-50% renal as unchanged, ~25% fecal.
Renal: 60-90% unchanged; biliary/fecal: minor (<10%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic